Pituitary neuroendocrine tumors (PitNETs) are the most common pituitary tumors and the
second most common brain tumors. Although the vast majority (> 90%) are benign, a small …

While recent progress has been made in identifying biomarkers of aggressive behavior and
new treatment options, many questions remain. Treatment decisions require …

Due to the current limited knowledge about the role of filamin A (FLNA) in pituitary tumour
progression, we aimed to analyse FLNA expression levels and its impact on aggressive …

Context Germline succinate dehydrogenase subunit B (SDHB) pathogenic variants are
characteristic of familial paraganglioma (PGL) syndrome type 4. This syndrome frequently …

Abstract Context and Objective The genetic profile of prolactinomas remains poorly
understood. Our objective is to identify somatic genetic alterations associated with …

Background Men with macroprolactinoma can present persistent hypogonadism despite
normoprolactinemia achieved with clinical and/or neurosurgical treatment. Usually …

The most common type of functioning pituitary adenomas is prolactinomas; unlike other
types, they are treated medically with dopamine agonists (DA). This treatment aims to …

Purpose At present, various treatment strategies are available for pituitary adenomas,
including medications, surgery and radiation. The guidelines indicate that pharmacological …

The priority treatment approach for prolactinomas is therapy with dopamine agonists, which
allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the …